LLY vs JNJ: Eli Lilly and Company vs Johnson & Johnson
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | LLY | JNJ |
|---|---|---|
| Company | Eli Lilly and Company | Johnson & Johnson |
| Price | $1,149.36 | $275.23 |
| Market Cap | $1.02T | $663.28B |
| P/E Ratio | 38.61 | 31.97 |
| EPS | $29.77 | $8.61 |
| Dividend Yield | 0.60% | 1.95% |
| 52-Week High | $1,292.65 | $281.07 |
| 52-Week Low | $712.05 | $173.33 |
| Beta | 0.50 | 0.23 |
| Return on Equity (ROE) | 102.29% | 25.74% |
| Debt-to-Equity | 162.07% | 57.71% |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYQ | NYQ |
| Employees | 50,000 | 138,200 |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →Roger Lowenstein's definitive biography of the world's most famous investor.
Check Price →Eli Lilly and Company and Johnson & Johnson both operate in the Healthcare sector. LLY has a market cap of $1.02T versus JNJ's $663.28B. On valuation, LLY carries a trailing P/E of 38.61 against 31.97 for JNJ. In terms of earnings, LLY posts EPS of $29.77 versus JNJ's $8.61. For price range, LLY has traded between $712.05 and $1,292.65 over the past 52 weeks, and JNJ between $173.33 and $281.07. On income, LLY yields 0.60% versus JNJ's 1.95%. On volatility, LLY carries the higher beta (LLY 0.50 vs JNJ 0.23), meaning it has historically moved more sharply than the market. How these figures compare depends on each company's growth profile, margins and competitive position — this snapshot is a starting point for research, not a recommendation.
Comparing two companies becomes much more powerful once you can read their financials directly — financial statement analysis guides are a practical next step. Many investors track comparisons like this in a dedicated stock research journal.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Eli Lilly and Company and Johnson & Johnson. This is not financial advice.
Recommended Reading
Jack Bogle's case for low-cost index funds, in under 300 pages.
Check Price →A structured logbook for tracking positions, theses and outcomes over time.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →